This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

NeoStem And Its Subsidiary, Progenitor Cell Therapy (PCT), To Present At Five Sessions At The 2014 Phacilitate Cell & Gene Therapy Forum

NEW YORK, Jan. 13, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization, announced today that NeoStem and PCT will present at five sessions at the Phacilitate Cell & Gene Therapy Forum 2014 in Washington DC.

Of particular note is the January 29 Breakfast Workshop hosted by PCT which will focus on PCT's Development by Design ("DbD") concept, aimed at helping PCT's clients methodically identify and address quality, cost, scale, and sustainability goals that are both challenging and critical for commercial-scale manufacture of cell therapy products.

"PCT's DbD methodology is designed to inform and accelerate the use of engineering principles and innovative solutions such as automation, integration, and closed system design, to provide a manufacturing process that will meet these commercial goals," said Brian Hampson, Senior Director, Engineering & Innovation services at PCT, and leader of the Workshop. "DbD provides a systems approach to guide strategy for manufacturing development and can be applied across the full range of cell-based therapeutic products."

The Company's other presentations range in topic from business to product characterization assays and a case study on CD34+ bone marrow stem cells in interventional cardiology.

"We are proud to showcase the depth and breadth of our resources at Phacilitate," Dr. Robert A. Preti, Chief Scientific Officer of PCT and NeoStem and President of PCT, "and demonstrate how PCT can provide solutions that help our clients achieve their cell therapy development and commercialization goals."

Phacilitate Cell & Gene Therapy Forum 2014 January 27-29, 2014 Grand Hyatt, Washington, DC

Monday, January 27, 2014

Session #1: Cell & Gene Therapy Business

  • Time: 9:00 AM EST
  • Speaker: Robert A. Preti, PhD, Chief Scientific Officer and President of PCT

Session #2: Product characterization assays – what are they good for?

  • Time: 12:25 PM EST
  • Speaker:Timothy Fong, PhD, MBA, Vice President, Technology &Product Development, PCT

Tuesday, January 28, 2014

Session: Challenges and future directions for commercial scale manufacturing

  • Time: 3:00 PM EST
  • Speaker: Brian Hampson, MS, Senior Director, Engineering & Innovation of PCT

Wednesday, January 29, 2014

Session #1: Development by Design (DbD) – A model for managing comparability risks and optimizing process development for Cell Therapy and Immunotherapy processes (Breakfast Workshop Hosted by PCT)

  • Time: 7:45 AM EST
  • Workshop leader: Brian Hampson, MS, Senior Director, Engineering & Innovation of PCT

Session #2: Case Study – CD34+ bone marrow stem cells: nature's blueprint for interventional cardiology

  • Time: 12:40 PM EST
  • Speaker: Jonathan Sackner-Bernstein, MD, FACC, Vice President, Clinical Development of NeoStem

About NeoStem, Inc.

NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs